Bio-Rad Laboratories, Inc. (BIO) to Release Quarterly Earnings on Monday
Bio-Rad Laboratories, Inc. (NYSE:BIO) will issue its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.54 per share for the quarter.
Bio-Rad Laboratories, Inc. (BIO) traded up 0.65% on Monday, hitting $223.39. 31,352 shares of the stock traded hands. The stock has a 50 day moving average of $223.03 and a 200 day moving average of $221.75. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79. The firm has a market capitalization of $6.62 billion, a PE ratio of 441.48 and a beta of 0.91.
WARNING: “Bio-Rad Laboratories, Inc. (BIO) to Release Quarterly Earnings on Monday” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/23/bio-rad-laboratories-inc-bio-to-release-quarterly-earnings-on-monday.html.
A number of research analysts recently weighed in on BIO shares. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 target price for the company. TheStreet downgraded shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $260.00.
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 28.29% of the stock is owned by insiders.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.